WilmerHale Advises Nodexus in $30M Series A Venture Financing

WilmerHale Advises Nodexus in $30M Series A Venture Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
WilmerHale has played a leading role in shaping the rules that govern the financial services industry in the United States.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Life Sciences

WilmerHale represented Nodexus Inc., an emerging leader in the development of automated live cell characterization and isolation technologies, in its $30M Series A financing that will allow the company to expand the manufacturing of its flagship NX One platform as well as build its commercialization capabilities and pipeline to meet an increasing demand.

The NX One system provides affordable walk-up usable automated single-cell sorting and dispensing to enable deployment into any lab working on bioprocessing, cancer biology research, gene editing and other expanding applications. The Series A funding will allow Nodexus to substantially grow its team and support its mission to “democratize biological tools.”

The WilmerHale team representing Nodexus was led by Joe Wyatt and included Molly Holsinger, Elise Brumbach and Sharon Baek.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel